Call for abstracts
There will be opportunities for researchers to present their own work within the scope of the Conference, either as a proffered paper or a poster. The scientific Program Committee invites submission of abstracts of original research in the topic areas listed below. In order to be considered for presentation, abstracts need to be submitted online before or on May 15, 2010. All abstracts will be reviewed by several independent experts. Notifications of acceptance or rejection, and scheduling information will be mailed to the submitting author within two weeks.

Topics for abstract submission

EP = Epidemiology
EP1 Epidemiology and Methods
EP2 Biomarkers of Exposure, Intermediate End Points, and Tumor Markers
EP3 Genetic Susceptibility to Cancer
EP4 Clinical Epidemiology of Cancer Survivorship and Behavioral Studies

CB = Cellular and Molecular Biology
CB1 Cell Growth Signaling Pathways
CB2 Cell Death and Senescence
CB3 Molecular Genetics
CB4 Oncogenes and Tumor Suppressor Genes
CB5 Gene Regulation and Transcription Factors
CB6 Epigenetics
CB7 Cell Cycle
CB8 DNA Damage and Repair
CB9 Metabolism and Cancer
CB10 Oncogenomics
CB11 Bioinformatics and Computational Molecular Biology
CB12 Innovative Technologies for Cancer Research
CB13 microRNAs and Other Non-Coding RNAs
CB14 Cancer Systems Biology

TB = Tumor Biology
TB1 Animal Models and Other Model Organisms
TB2 Stem Cell Biology/Cancer Stem Cells/Developmental Oncobiology
TB3 Tumor Adhesion, Migration, and Invasion
TB4 Tumor Metastasis
TB5 Angiogenesis, Microcirculation, and Cellular Microenvironment
TB6 Tumor Microenvironment
TB7 In Vivo Imaging
TB8 Pediatric Cancer – Basic Science
TB9 Radiation Biology

CG = Carcinogenesis
CG1 Carcinogenesis – Chemical, Viral, and Radiation

CH = Cancer Chemistry
CH1 Drug Discovery and Design
CH2 Structural Biology
CH3 Proteomics, Metabolomics, and Biological
CH4 Chemical Aspects of Carcinogenesis
CH5 Imaging Agents and Radio therapeutics
CH6 Chemical Biology

CL = Clinical Research
CL1 Translational Research – Molecular Biology in the Clinic
CL2 Phase I Clinical Trials and Clinical Pharmacology
CL3 Phase II and Phase III Adult Clinical Trials (Organ Site-specific)
CL4 Pediatric Cancer – Clinical Investigations
CL5 Clinical Research in the Elderly
CL6 Clinical Research in Minorities and Medically Underserved Populations
CL7 Biostatistics in Clinical Trials
CL8 Ethics in Clinical Trials
CL9 Clinical Immunology/Biological Therapy
CL10 Radiation Oncology
CL11 Clinical Endocrinology
CL12 Supportive Care and Survivorship Research
CL13 Molecular Biomarkers for Diagnosis, Prognosis, and Prediction

EN = Endocrinology
EN1 Molecular and Preclinical Endocrinology
EN2 Clinical Endocrinology

ET = Experimental and Molecular Therapeutics
ET1 Drug Discovery
ET2 New Molecular Targets
ET3 Mechanisms of Drug Action
ET4 Drug Resistance
ET5 Pharmacology, Pharmacogenetics, and Pharmacogenomics
ET6 Small Molecule Therapeutic Agents
ET7 Biological Therapeutic Agents
ET8 Gene and Vector-based Therapy
ET9 Preclinical Radiotherapeutics

IM = Immunology
IM1 Tumor Immunology and Biology
IM2 Cancer Immunotherapy in Preclinical and Clinical

PR = Prevention Research
PR1 Preclinical Prevention Studies
PR2 Clinical Prevention Studies
PR3 Behavioral and Social Science in Cancer and Prevention Research

Further information, should contact:
Nancy Jiang
Program Coordinator
E-mail: nancy@cancercon.com
Abstract submission for the 3rd World Cancer Conference 2010
Fields marked with an asterisk * are mandatory fields throughout the abstract submission process.